Antibiotic-induced cardiac arrhythmias

Cardiovascular Therapeutics

Volumn 32, Issue 1, 2014, Pages 19-25

  Abo Salem, Elsayed ^a   Fowler, John C ^b   Attari, Mehran ^a   Cox, Craig D ^c   Perez Verdia, Alejandro ^b   Panikkath, Ragesh ^b   Nugent, Kenneth ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antibiotics; Fluoroquinolones; Macrolides; QT interval; Torsade de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; MACROLIDE; QUINOLONE DERIVATIVE;

ARRHYTHMOGENESIS; BRADYCARDIA; CARDIOVASCULAR RISK; DRUG INDUCED DISEASE; DRUG INTERACTION; DRUG POTENCY; DRUG SCREENING; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART REPOLARIZATION; HIGH RISK POPULATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; TORSADE DES POINTES;

ANTIBIOTICS; FLUOROQUINOLONES; MACROLIDES; QT INTERVAL; TORSADE DE POINTES;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FLUOROQUINOLONES; HUMANS; MACROLIDES; TORSADES DE POINTES;

EID: 84892495535     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12054     Document Type: Review

References (82)

1. Freeman BD, Dixon DJ, Coopersmith CM, Zehnbauer BA, Buchman TG. Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients. Pharmacoepidemiol Drug Saf 2008;17:971-981.
2. Curtis LH, Østbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-141.
3. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H. Hospital consumption of antibiotics in 15 European countries: results of the ESAC retrospective data collection (1997-2002). J Antimicrob Chemother 2006;58:159-167.
4. Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. Br J Clin Pharmacol 2009;67:88-98.
5. Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003;28:282-90.
6. Antzelevitch C, Sun Z-Q, Zhang Z-Q, Yan G-X. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and Torsade de Pointes. J Am Coll Cardiol 1996;28:1836-1848.
7. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001;296:806-810.
8. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human Ether-a-Go-Go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002;302:320-327.
9. Bischoff U, Schmidt C, Netzer R, Pongs O. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000;406:341-3.
10. Mitcheson JS. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci 2000;97:12329-12333.
11. Duncan RS, Ridley JM, Dempsey CE, et al. Erythromycin block of the HERG K+ channel: accessibility to F656 and Y652. Biochem Biophys Res Commun 2006;341:500-506.
12. Alexandrou AJ, Duncan RS, Sullivan A, et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br J Pharmacol 2006;147:905-16.
13. Adamantidis MM, Dumotier BM, Caron JF, Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam Clin Pharmacol 2009;12:70-76.
14. Seop Kim D, Kim KS, Hwan Choi K, et al. Electrophysiological safety of novel fluoroquinolone antibiotic agents gemifloxacin and balofloxacin. Drug Chem Toxicol 2006;29:303-12.
15. Chen X, Cass JD, Bradley JA, et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 2009;146:792-799.
16. Hagiwara T, Satoh S, Kasai Y, Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn J Pharmacol 2001;87:231-234.
17. Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 2007;577:222-32.
18. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin- associated long QT syndrome. Circulation 1993;88:1832-1844.
19. Milberg P, Eckardt L, Bruns H-J, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar qt prolongation: fast phase 3 repolarization prevents early afterdepolarizations and Torsade de Pointes. J Pharmacol Exp Ther 2002;303:218-225.
20. Milberg P, Hilker E, Ramtin S, et al. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict Torsades de Pointes. J Cardiovasc Electrophysiol 2007;18:647-654.
21. Sicouri S, Antzelevitch C. Drug-induced afterdepolarizations and triggered activity occur in a discrete subpopulation of ventricular muscle cells (M cells) in the canine heart: quinidine and digitalis. J Cardiovasc Electrophysiol 1993;4:48-58.
22. Patmore L, Fraser S, Mair D, Templeton A. Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur J Pharmacol 2000;406:449-452.
23. Gintant G. An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 2011;129:109-19.
24. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical qt interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
25. Cavero I. Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs. Eur Heart J Suppl 2001;3:K53-K63.
26. Wisialowski T, Crimin K, Engtrakul J, O'Donnell J, Fermini B, Fossa AA. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther 2006;318:352-359.
27. Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses|[ast]. Clin Pharmacol Ther 2003;73:292-303.
28. Demolis JL, Charransol A, Funck-Brentano C, Jaillon P. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 2003;41:499-503.
29. Basyigit I, Kahraman G, Ilgazli A, Yildiz F, Boyaci H. The effects of levofloxacin on ECG parameters and late potentials. Am J Ther 2005;12:407-10.
30. Rosignoli MT, Di Loreto G, Dionisio P. Effects of prulifloxacin on cardiac repolarization in healthy subjects. Clin Drug Investig 2010;30:5-14.
31. Taubel J, Naseem A, Harada T, et al. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. Br J Clin Pharmacol 2010;69:391-400.
32. Tsikouris JP, Peeters MJ, Cox CD, Meyerrose GE, Seifert CF. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 2006;11:52-56.
33. Haq S KM, Holt J, Kassotis J. The effects of intravenous levofloxacin on the QT interval and QT dispersion. Int J Angiol 2006;15:16-19.
34. Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004;44:464-473.
35. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-1472.
36. Ray Wa, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
37. Stanat SJC, Carlton CG, Crumb WJ, Agrawal KC, Clarkson CW. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 2003;254:1-7.
38. Schoenenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (Torsades de Pointes). BMJ 1990;300:1375-1375.
39. Freeman JPR. Erythromycin prolongs the QTc interval among patients with pneumonia. Pharmacoepidemiol Drug Saf 1997;6:13-9.
40. Mishra A, Friedman HS, Sinha AK. The Effects of erythromycin on the electrocardiogram. Chest 1999;115:983-986.
41. Oberg KC, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995;15:687-92.
42. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of Torsades De Pointes associated with macrolide use: review of the united states food and drug administration adverse event reporting system. Clin Infect Dis 2002;35:197-200.
43. Haarst ADv, Klooster GAEvt, Gerven JMAv, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998;64:542-546.
44. Strle F, Maraspin V. Is azithromycin treatment associated with prolongation of the Q-Tc interval? Wien Klin Wochenschr 2002;114:396-9.
45. Song Z, Brassard P, Brophy JM. A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases. Can J Cardiol 2008;24:391-5.
46. Hsieh M-H, Chen S-A, Chiang C-E, et al. Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Int J Cardiol 1996;54:85-88.
47. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de Pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 2006;22:672-674.
48. Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003;116:U666.
49. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
50. Gluud C, Als-Nielsen B, Damgaard M, et al. Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008;111:280-287.
51. Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368:1704-12.
52. Guo J, Zhan S, Lees-Miller JP, Teng G, Duff HJ. Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37°C and 42°C. Heart Rhythm 2005;2:860-866.
53. Kirsch GE, Trepakova ES, Brimecombe JC, et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004;50:93-101.
54. Yao J-A, Du X, Lu D, Baker RL, Daharsh E, Atterson P. Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature. J Pharmacol Toxicol Methods 2005;52:146-153.
55. Davie C, Pierre-Valentin J, Pollard C, et al. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel. J Cardiovasc Electrophysiol 2004;15:1302-9.
56. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999;84:989-998.
57. Justo D, Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med 2006;17:254-259.
58. LaPointe NM, Curtis LH, Chan KA, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 2006;15:361-368.
59. Baptista R, Silva S, Dias P, Monteiro P, Feio J, Providencia LA. In-hospital prescription of QT-prolonging drugs in a cohort of more than 100, 000 patients. Int J Cardiol 2011;147:165-6.
60. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992;52:231-8.
61. Roden DM, Long QT. Syndrome: reduced repolarization reserve and the genetic link. J Intern Med 2005;259:59-69.
62. Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990;89:235-8.
63. Koh TW. Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol 2001;24:1575-6.
64. Orban Z, MacDonald LL, Peters MA, Guslits B. Erythromycin-induced cardiac toxicity. Am J Cardiol 1995;75:859-61.
65. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529-533.
66. Hinterseer M, Beckmann B-M, Thomsen MB, et al. Relation of increased short-term variability of QT interval to congenital long-QT syndrome. Am J Cardiol 2009;103:1244-1248.
67. Varró A, Papp JG. Low penetrance, subclinical congenital LQTS: concealed LQTS or silent LQTS? Cardiovasc Res 2006;70:404-406.
68. Makita N, Horie M, Nakamura T, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002;106:1269-1274.
69. Hinterseer M, Irlbeck M, Ney L, et al. Acute respiratory distress syndrome with transiently impaired left ventricular function and Torsades De Pointes arrhythmia unmasking congenital long QT syndrome in a 25-yr-old woman. Br J Anaesth 2006;97:150-153.
70. Itoh H, Sakaguchi T, Ding W-G, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome CLINICAL PERSPECTIVE. Circ Arrhythm Electrophysiol 2009;2:511-523.
71. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated Torsades de Pointes. Heart Rhythm 2007;4:603-607.
72. Jeyaraj D, Abernethy DP, Natarajan RN, et al. I(Kr) channel blockade to unmask occult congenital long QT syndrome. Heart Rhythm 2008;5:2-7.
73. Aiba T, Shimizu W, Inagaki M, et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005;45:300-307.
74. Luo X, Xiao J, Lin H, Lu Y, Yang B, Wang Z. Genomic structure, transcriptional control, and tissue distribution of HERG1 and KCNQ1 genes. Am J Physiol Heart Circ Physiol 2008;294:H1371-H1380.
75. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr Potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-187.
76. Paulussen AD, Gilissen RA, Armstrong M, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004;82:182-8.
77. Poluzzi E, Raschi E, Motola D, Moretti U, de Ponti F. Antimicrobials and the risk of Torsades de Pointes: the contribution from data mining of the US FDA adverse event reporting system. Drug Saf 2010;33:303-314.
78. Conrath CE, Wilde AAM, Jongbloed RJE, et al. Gender differences in the long QT syndrome: effects of β-adrenoceptor blockade. Cardiovasc Res 2002;53:770-776.
79. Drici MD. Cardiac actions of erythromycin: influence of female sex. JAMA 1998;280:1774-1776.
80. Abo-Salem E, Nugent K, Chance W. Antibiotic-induced cardiac arrhythmia in elderly patients. J Am Geriatr Soc 2011;59:1747-9.
81. Morganroth J, DiMarco JP, Anzueto A, Niederman MS, Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia*. Chest 2005;128:3398-3406.
82. Samaha FF. QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 1999;107:528-529.